NASDAQ:RNA

Avidity Biosciences - RNA News Today

$20.09

+0.31 (+1.57%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $19.68
▼
$20.28
50-Day Range: $19.56
▼
$25.65
52-Week Range: $9.83
▼
$25.74

Volume: 471,360 shs
Average Volume: 1.07 million shs
Market Capitalization: $1.42 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.60

Institutional Ownership

Headlines

Short Interest

Social Media

Get Avidity Biosciences News Delivered to You Automatically

RNA Media Mentions By Week

RNA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNA
News Sentiment
▼
1.27

0.61
▲
Average
Medical
News Sentiment

RNA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNA Articles
This Week
▼
2

1
▲
RNA Articles
Average Week

Source

Source	Headline
	Avidity Biosciences (NASDAQ:RNA) Shares Down 3.6% americanbankingnews.com - March 24 at 8:48 AM
	Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference finance.yahoo.com - March 13 at 7:41 PM
	Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells seekingalpha.com - March 11 at 5:21 PM
	Avidity Biosciences (RNA) Receives a Buy from Credit Suisse markets.businessinsider.com - March 1 at 2:32 PM
	Avidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights finanznachrichten.de - March 1 at 9:31 AM
	Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights finance.yahoo.com - March 1 at 9:31 AM
	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com - March 1 at 9:31 AM
	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock finance.yahoo.com - February 27 at 5:05 PM
	Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform finance.yahoo.com - February 27 at 10:55 AM
	Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader finance.yahoo.com - February 23 at 9:08 AM
	Avidity's AOC 1020 Gets FDA Orphan Drug Designation For Muscular Dystrophy Treatment markets.businessinsider.com - February 14 at 1:36 PM
	Avidity Biosciences Gets FDA Orphan Designation for AOC 1020 >RNA marketwatch.com - February 14 at 1:36 PM
	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy finance.yahoo.com - February 14 at 1:36 PM
	Avidity Biosciences to Participate in Upcoming Investor Conference finance.yahoo.com - February 7 at 9:16 AM
	The one-year returns have been notable for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasing finance.yahoo.com - February 2 at 10:19 AM
	Avidity's therapy for rare muscle disorder gets FDA fast track status msn.com - January 18 at 2:54 PM
	Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy finance.yahoo.com - January 18 at 9:54 AM
	Peering Into Avidity Biosciences's Recent Short Interest msn.com - January 3 at 1:26 PM
	Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics seekingalpha.com - December 23 at 8:30 AM
	Following a 16% decline over last year, recent gains may please Avidity Biosciences, Inc. (NASDAQ:RNA) institutional owners finance.yahoo.com - December 23 at 8:30 AM
	Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology seekingalpha.com - December 22 at 6:55 AM
	Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform seekingalpha.com - December 21 at 6:49 AM
	This Genetic Medicine Stock Soared Over 50% on Industry First msn.com - December 15 at 3:21 PM
	This Genetic Medicine Stock Soars Over 50% on Industry First finance.yahoo.com - December 14 at 11:37 PM
	Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial finance.yahoo.com - December 14 at 6:37 PM
	Expert Ratings for Avidity Biosciences markets.businessinsider.com - December 14 at 6:37 PM
	How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere finance.yahoo.com - December 14 at 1:36 PM
	Avidity Reports Effective Delivery Of SiRNA Into Muscle; Shows Meaningful DMPK Reduction markets.businessinsider.com - December 14 at 8:36 AM
	Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics finance.yahoo.com - December 14 at 8:36 AM
	Avidity's stock rallies 39% on new RNA data finance.yahoo.com - December 14 at 8:36 AM
	RNA Sequencing Analysis Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028 marketwatch.com - December 13 at 6:16 AM
	Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA) finance.yahoo.com - November 18 at 1:29 PM
	Avidity Biosciences Third Quarter 2022 Earnings: Beats Expectations finance.yahoo.com - November 11 at 9:47 AM
	Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights finance.yahoo.com - November 8 at 4:23 PM
	Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping finance.yahoo.com - October 11 at 9:02 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA benzinga.com - October 6 at 7:15 PM
	Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society finance.yahoo.com - October 6 at 2:15 PM
	Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy finance.yahoo.com - September 29 at 10:23 AM
	U.S. FDA puts Avidity's muscle disorder drug trial on partial hold msn.com - September 28 at 2:57 AM
	FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial finance.yahoo.com - September 27 at 4:56 PM
	Avidity: FDA Places Partial Clinical Hold On Participant Enrollment In Phase 1/2 MARINA Trial nasdaq.com - September 27 at 11:55 AM
	Twitter, JetBlue, Lucid Group Rise Premarket; Avidity, Ferguson Fall msn.com - September 27 at 11:55 AM
	U.S. FDA puts Avidity's muscle disorder drug study on hold msn.com - September 27 at 11:55 AM
	Avidity Biosciences: FDA Places Partial Hold on AOC 1001 Study >RNA marketwatch.com - September 27 at 11:55 AM
	Avidity Biosciences Shares Slide on Partial FDA Study Hold >RNA marketwatch.com - September 27 at 11:55 AM
	Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial finance.yahoo.com - September 27 at 11:55 AM
	Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial finance.yahoo.com - September 27 at 11:55 AM
	Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study finance.yahoo.com - September 27 at 11:55 AM
	Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs finance.yahoo.com - September 7 at 8:11 AM
	The one-year returns have been for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasing nasdaq.com - August 20 at 11:12 PM

Get Avidity Biosciences News Delivered to You Automatically

This page (NASDAQ:RNA) was last updated on 3/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avidity Biosciences - RNA News Today

RNA Media Mentions By Week

RNA Media Sentiment

RNA News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info